Adjunctive brexpiprazole 1 mg and 2 mg daily for Japanese patients with major depressive disorder following inadequate response to antidepressants: a phase 2/3, randomized, double‐blind ( BLESS ) study
Psychiatry and Clinical Neurosciences · 2024-02 · 78 (2) · 113-122
DOI: 10.1111/pcn.13615 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Psychiatry and Clinical Neurosciences, 2023-12. Verfasst von Masaki Kato und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neuropsychiatry, Kansai Medical University, Osaka, Japan. Hauptthemen laut MEDLINE: Major Depressive Disorder, Thiophenes, Quinolones. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Otsuka Pharmaceutical Co., Ltd., Otsuka Pharmaceutical.
Abstract (Originalsprache)
Aims
Inadequate antidepressant response interrupts effective treatment of major depressive disorder (MDD). The BLESS study evaluates the dosage, efficacy, and safety of brexpiprazole adjunctive therapy in Japanese patients with inadequate antidepressant therapy (ADT) response.
Methods
This placebo‐controlled, randomized, multicenter, parallel‐group phase 2/3 study randomized Japanese MDD patients (Hamilton Rating Scale for Depression 17‐item total score ≥ 14; historical inadequate response to 1–3 ADTs) with inadequate response to 8‐week single‐blind, prospective SSRI/SNRI treatment to 6‐week adjunctive treatment with brexpiprazole 1 mg, 2 mg, or placebo. The primary endpoint was change in Montgomery‐Åsberg Depression Rating Scale (MADRS) total score from baseline. Secondary endpoints included MADRS response, remission rate, and Clinical Global Impression‐Improvement score. Safety was comprehensively evaluated, especially regarding antipsychotic adverse events (AEs).
Results
Of 1194 screened patients, 740 were randomized and 736 (1 mg, n = 248; 2 mg, n = 245; placebo, n = 243) had ≥1 baseline/post‐baseline MADRS total score. The LSM (SE) change from baseline in MADRS total score at Week 6 by MMRM analysis was −8.5 (0.47) with brexpiprazole 1 mg, −8.2 (0.47) with brexpiprazole 2 mg, and −6.7 (0.47) with placebo (placebo‐adjusted LSM difference [95% CI]: 1 mg, −1.7 [−3.0, −0.4]; P = 0.0089; 2 mg, −1.4 [−2.7, −0.1]; P = 0.0312). Secondary efficacy results supported the primary endpoint. Brexpiprazole was generally well tolerated.
Conclusion
Brexpiprazole 1 mg daily was an appropriate starting dose and both 1 mg and 2 mg daily were effective and well tolerated as adjunctive therapy for Japanese MDD patients not adequately responsive to ADT.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Neuropsychiatry, Kansai Medical University, Osaka, Japan.
- Clinical Development, Headquarters of Clinical Development Otsuka Pharmaceutical Co. Ltd., Tokyo, Japan.
- Clinical Development, Headquarters of Clinical Development Otsuka Pharmaceutical Co. Ltd., Osaka, Japan.
- Medical Affairs, Otsuka Pharmaceutical Co., Ltd., Tokyo, Japan.
- Medical Affairs, Otsuka Pharmaceutical Co., Ltd., Tokushima, Japan.
- Japan Depression Center, Tokyo, Japan.
ORCID-Profile: Masaki Kato, Yuki Isogai
Förderung
- Otsuka Pharmaceutical Co., Ltd.
- Otsuka Pharmaceutical
Zitieren
APA
Kato, M., Shiosakai, M., Kuwahara, K., Iba, K., Shimada, Y., Saito, M., Isogai, Y., Sekine, D., Aoki, K., Koga, N., & Higuchi, T. (2024). Adjunctive brexpiprazole 1 mg and 2 mg daily for Japanese patients with major depressive disorder following inadequate response to antidepressants: a phase 2/3, randomized, double‐blind ( BLESS ) study. Psychiatry and Clinical Neurosciences, 78(2), 113-122. https://doi.org/10.1111/pcn.13615
Vancouver
Kato M, Shiosakai M, Kuwahara K, Iba K, Shimada Y, Saito M, et al. Adjunctive brexpiprazole 1 mg and 2 mg daily for Japanese patients with major depressive disorder following inadequate response to antidepressants: a phase 2/3, randomized, double‐blind ( BLESS ) study. Psychiatry and Clinical Neurosciences. 2024;78(2):113-122. doi:10.1111/pcn.13615
BibTeX
@article{Kato2024,
author = {Kato, Masaki and Shiosakai, Masako and Kuwahara, Kazuo and Iba, Katsuhiro and Shimada, Yuki and Saito, Mizuki and Isogai, Yuki and Sekine, Daisuke and Aoki, Kazuo and Koga, Nobuyuki and Higuchi, Teruhiko},
title = {Adjunctive brexpiprazole 1 mg and 2 mg daily for Japanese patients with major depressive disorder following inadequate response to antidepressants: a phase 2/3, randomized, double‐blind ( BLESS ) study},
journal = {Psychiatry and Clinical Neurosciences},
year = {2024},
volume = {78},
number = {2},
pages = {113--122},
doi = {10.1111/pcn.13615}
}
EUVIMED